



Figure S1. Flow cytometric analysis of MCF-7 (**A**) and MDA-MB-231 (**B**) breast cancer cells treated for 24 h with **1-3** and etoposide for active caspase-8 in the absence or presence of pan-caspase inhibitor (Z-VAD-FMK 100 μ M). The compounds were tested at the following concentrations: **1** (10 μ g/ml/23.83 μ M, 20 μ g/ml/47.66 μ M), **2** (10 μ g/ml/22.75 μ M, 20 μ g/ml/45.50 μ M), **3** (10 μ g/ml/23.78 μ M, 20 μ g/ml/47.56 μ M), **etoposide** (10 μ g/ml/17 μ M, 20 μ g/ml/34 μ M). Mean percentage values from three independent experiments (n=3) done in duplicate are presented. **p < 0.01 vs. control (Z-VAD-FMK 100 μ M) group, ***p < 0.001 vs. control (Z-VAD-FMK 100 μ M) group.







Figure S2. Flow cytometric analysis of MCF-7 (**A**) and MDA-MB-231 (**B**) breast cancer cells treated for 24 h with **1-3** and etoposide for active caspase-9 in the absence or presence of pan-caspase inhibitor (Z-VAD-FMK 100 μ M). The compounds were tested at the following concentrations: **1** (10 μ g/ml/23.83 μ M, 20 μ g/ml/47.66 μ M), **2** (10 μ g/ml/22.75 μ M, 20 μ g/ml/45.50 μ M), **3** (10 μ g/ml/23.78 μ M, 20 μ g/ml/47.56 μ M), **etoposide** (10 μ g/ml/17 μ M, 20 μ g/ml/34 μ M). Mean percentage values from three independent experiments (n=3) done in duplicate are presented. **p < 0.01 vs. control (Z-VAD-FMK 100 μ M) group, ***p < 0.001 vs. control (Z-VAD-FMK 100 μ M) group.